Clamoring for ACCESS: New CMS 10-year payment model gets more than 150 applicants

CMS’s new 10-year ACCESS model has attracted more than 150 applicants, with the application deadline extended to May 15 ahead of the July start. The program shifts Medicare chronic-care reimbursement toward outcome-based monthly payments, includes a 50/50 payment withhold, and may waive the standard 20% coinsurance for participating patients. CMS also says health plans covering 165 million members have committed to aligning payment approaches, supporting broader adoption across Medicare Advantage, Medicaid and commercial coverage.

Analysis

This is less a single CMS pilot than an attempted re-pricing of the chronic-care stack: if outcomes become the billing unit, the economic moat shifts away from visit volume and toward data capture, adherence, and care-navigation software. The near-term winners are the non-hospital vendors that can aggregate patients across fragmented primary care, because they can amortize fixed tech, coaching, and analytics costs across a larger panel and earn the upside from better endpoint performance. That also puts pressure on incumbents whose revenue depends on episodic encounters rather than measurable longitudinal control.

The second-order effect is a likely acceleration of referral-network consolidation. Primary care groups may not join directly, but they become channel partners, and the public reporting element gives them a cheap due-diligence layer to steer patients toward the highest-performing platforms. Over 6-18 months, that should increase share for platforms with strong interoperability, remote monitoring, and payer contracting infrastructure, while leaving smaller point-solution vendors exposed to being bundled or displaced.

The biggest risk is not adoption; it is model gaming and implementation drag. If outcome thresholds tighten faster than behavior change can show up, margin pressure could hit participants before utilization savings arrive, creating churn in the applicant cohort and slowing private-payer follow-through. A more subtle downside is that waived coinsurance may boost engagement, but if the model attracts more severe patients, reported outcomes could look worse in year one even if absolute care quality improves.

Consensus is likely underestimating how slowly savings will show up relative to headline optimism. The first-order market reaction should favor "picks and shovels" data and remote-care enablers, but the durable alpha is in companies that can prove they reduce total cost of care without sacrificing provider workflow. If this becomes a template for commercial payers, the eventual value transfer could be meaningful, but the adoption curve and attribution rules will determine whether this is a multi-year margin tailwind or just another pilot with noisy optics.

Key Decisions for Investors

• Long a basket of remote-patient-monitoring / chronic-care platform names versus hospital-heavy providers over 6-12 months; the former capture the economics of longitudinal management while the latter face margin dilution from avoided visits.
• Initiate a pair trade: long tech-enabled care coordination vendors and short high-utilization primary care / ambulatory names with limited interoperability advantage; thesis is referral steering and public scorecards will concentrate patient flow toward better-performing platforms.
• Buy call spreads on healthcare software / interoperability beneficiaries with 9-18 month horizon; upside is a multi-payer alignment cycle, while risk is slower CMS implementation and delayed commercial adoption.
• Avoid chasing the first applicant cohort indiscriminately; prefer names with proven data integration and contract structure, because year-one performance dispersion and withhold mechanics create a real probability of payment leakage.